Lupus Nephritis
Manifestations, Complications, and Comorbidities of Lupus
Epidemiology of Lupus
Overview of Lupus
Types of Lupus
CAR T-cell therapy may be a ‘miracle,’ but it is too soon to say ‘cure’
It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.
SGLT2 inhibitors slash risks for lupus nephritis, heart failure in SLE, type 2 diabetes
Treatment with sodium-glucose cotransporter-2 inhibitors significantly lowered risks for lupus nephritis, dialysis and kidney transplant for patients with systemic lupus erythematosus and type 2 diabetes, according to data.
Patient with lupus treated with KYV-101 CAR T-cell therapy relapses after 5 months
A patient with lupus nephritis treated with KYV-101, a chimeric antigen receptor T-cell immunotherapy, saw their disease return 5 months after initially showing a response to the treatment, according to the manufacturer.
Top in rheumatology: Steroid dosing for lupus nephritis; Benlysta decreases lupus flares
A systemic review and meta-analysis revealed that higher initial glucocorticoid doses improved lupus nephritis treatment response but increased risks for serious infections and mortality.
Higher steroid dose improves lupus nephritis renal outcomes, raises mortality risk
Patients with lupus nephritis who receive higher initial doses of glucocorticoids demonstrate improved renal outcomes, albeit with increased serious infection and mortality risks, according to data published in Arthritis & Rheumatology.
Serology ‘significantly different’ between membranous vs. proliferative lupus nephritis
Proteinuria levels are not predictive of membranous lupus nephritis vs. proliferative lupus nephritis, according to data published in Rheumatology.